Skip to main content
Erschienen in: Clinical Reviews in Allergy & Immunology 2/2007

01.04.2007

Antiphospholipid Syndrome and Cognition

verfasst von: Bernardo Liberato, Roger A. Levy

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

In addition to the well-defined neurologic events due to arterial and venous thrombotic vascular occlusions of antiphospholipid syndrome (APS), a broad spectrum of neuropsychiatric has been related to antiphospholipid (aPL). Experimental evidence of a pathogenic role of aPL in mice with impaired neurological function disclosed inflammatory reaction as a hallmark. The process that leads to neurological dysfunction seems to be both structurally destructive and functionally impairing. The most modern resources of neuroimmaging also suggest that, in addition to the micro-infarcts that occur in strategic areas, other metabolic impairments are related to progressive dementia and aPL presence. Although there is a lot of confusion among APS and lupus’ cognitive involvement, there is a body of experimental and clinical evidence that aPL causes this kind of damage.
Literatur
1.
Zurück zum Zitat Sanna G, Bertolaccini ML, Cuadrado MJ et al (2003) Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology 42:200–213PubMedCrossRef Sanna G, Bertolaccini ML, Cuadrado MJ et al (2003) Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology 42:200–213PubMedCrossRef
2.
Zurück zum Zitat Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD (1997) Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest 100(3):613–619PubMedCrossRef Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD (1997) Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest 100(3):613–619PubMedCrossRef
3.
Zurück zum Zitat Hess DC, Taormina M, Thompson J et al (1993) Cognitive and neurologic deficits in the MRL/lpr mouse: a clinicopathologic study. J Rheumatol 20(4):610–617PubMed Hess DC, Taormina M, Thompson J et al (1993) Cognitive and neurologic deficits in the MRL/lpr mouse: a clinicopathologic study. J Rheumatol 20(4):610–617PubMed
4.
Zurück zum Zitat Shoenfeld Y, Nahum A, Korczyn AD et al (2003) Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 12:436–442PubMedCrossRef Shoenfeld Y, Nahum A, Korczyn AD et al (2003) Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 12:436–442PubMedCrossRef
5.
Zurück zum Zitat Caronti B, Pittoni V, Palladini G, Valesini G (1998) Anti-beta 2-glycoprotein I antibodies bind to central nervous system. J Neurol Sci 156(2):211–219PubMedCrossRef Caronti B, Pittoni V, Palladini G, Valesini G (1998) Anti-beta 2-glycoprotein I antibodies bind to central nervous system. J Neurol Sci 156(2):211–219PubMedCrossRef
6.
Zurück zum Zitat Caronti B, Calderaro C, Alessandri C et al (1998) Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J Autoimmun 11(5):425–429PubMedCrossRef Caronti B, Calderaro C, Alessandri C et al (1998) Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J Autoimmun 11(5):425–429PubMedCrossRef
7.
Zurück zum Zitat Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD (1999) Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 8(2):127–133PubMedCrossRef Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD (1999) Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 8(2):127–133PubMedCrossRef
8.
Zurück zum Zitat Cimaz R, Meroni PL, Shoenfeld Y (2006) Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughe’s syndrome). Lupus 15(4):191–197PubMedCrossRef Cimaz R, Meroni PL, Shoenfeld Y (2006) Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughe’s syndrome). Lupus 15(4):191–197PubMedCrossRef
9.
Zurück zum Zitat Chinn RJ, Wilkinson ID, Hall-Craggs MA et al (1997) Magnetic resonance imaging of the brain and cerebral proton spectroscopy in patients with systemic lupus erythematosus. Arthritis Rheum 40(1):36–46PubMedCrossRef Chinn RJ, Wilkinson ID, Hall-Craggs MA et al (1997) Magnetic resonance imaging of the brain and cerebral proton spectroscopy in patients with systemic lupus erythematosus. Arthritis Rheum 40(1):36–46PubMedCrossRef
10.
Zurück zum Zitat Kozora E, West SG, Kotzin BL et al (1998) Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 41(1):41–47PubMedCrossRef Kozora E, West SG, Kotzin BL et al (1998) Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 41(1):41–47PubMedCrossRef
11.
Zurück zum Zitat Hilker R, Thiel A, Geisen C, Rudolf J (2000) Cerebral blood flow and glucose metabolism in multi-infarct-dementia related to primary antiphospholipid antibody syndrome. Lupus 9(4):311–316PubMedCrossRef Hilker R, Thiel A, Geisen C, Rudolf J (2000) Cerebral blood flow and glucose metabolism in multi-infarct-dementia related to primary antiphospholipid antibody syndrome. Lupus 9(4):311–316PubMedCrossRef
12.
Zurück zum Zitat Sibbitt WL Jr, Haseler LJ, Griffey RR et al Neurometabolism of active neuropsychiatric lupus determined with proton MR spectroscopy. Am J Neuroradiol YEAR 18:1271–1277 Sibbitt WL Jr, Haseler LJ, Griffey RR et al Neurometabolism of active neuropsychiatric lupus determined with proton MR spectroscopy. Am J Neuroradiol YEAR 18:1271–1277
13.
Zurück zum Zitat Sabet A, Sibbitt WL Jr, Stidley CA et al (1998) Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. Stroke 29:2254–2260PubMed Sabet A, Sibbitt WL Jr, Stidley CA et al (1998) Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. Stroke 29:2254–2260PubMed
14.
Zurück zum Zitat Kozora E, Arciniegas DB, Filley CM et al (2005) Cognition, MRS neurometabolites, and MRI volumetrics in non-neuropsychiatric systemic lupus erythematosus: preliminary data. Cogn Behav Neurol 18(3):159–162PubMedCrossRef Kozora E, Arciniegas DB, Filley CM et al (2005) Cognition, MRS neurometabolites, and MRI volumetrics in non-neuropsychiatric systemic lupus erythematosus: preliminary data. Cogn Behav Neurol 18(3):159–162PubMedCrossRef
15.
Zurück zum Zitat Appenzeller S, Li LM, Costallat L, Cendes F (2005) Evidence of reversible axonal dysfunction in systemic lupus erythematosus: a proton MRS study. Brain 128(12):2933–2940PubMedCrossRef Appenzeller S, Li LM, Costallat L, Cendes F (2005) Evidence of reversible axonal dysfunction in systemic lupus erythematosus: a proton MRS study. Brain 128(12):2933–2940PubMedCrossRef
16.
Zurück zum Zitat Castellino G, Govoni M, Padovan M et al (2005) Proton magnetic resonance spectroscopy may predict future brain lesions in SLE patients: a functional multi-imaging approach and follow up. Ann Rheum Dis 64:1022–1027PubMedCrossRef Castellino G, Govoni M, Padovan M et al (2005) Proton magnetic resonance spectroscopy may predict future brain lesions in SLE patients: a functional multi-imaging approach and follow up. Ann Rheum Dis 64:1022–1027PubMedCrossRef
Metadaten
Titel
Antiphospholipid Syndrome and Cognition
verfasst von
Bernardo Liberato
Roger A. Levy
Publikationsdatum
01.04.2007
Verlag
Humana Press Inc
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 2/2007
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-007-0007-x

Weitere Artikel der Ausgabe 2/2007

Clinical Reviews in Allergy & Immunology 2/2007 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.